ORLANDO, Fla. - The full presentation of the C-08 trial of Roche/Genentech'sAvastin for use as adjuvant therapy in colorectal cancer - a landmark trial that failed to show an advantage for bevacizumab - at the American Society of Clinical Oncology annual meeting gave the sponsors some signs of encouragement
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
